EMA proposes researchers should have controlled access to raw drug trial data
This article was originally published in SRA
Executive Summary
Independent researchers seeking access to patient-level clinical trial data (ie raw trial data) in EU drug marketing authorization applications may be allowed "controlled access" to such information in certain circumstances under new proposals issued by the European Medicines Agency1,2.